Urovant Sciences: peers
Urovant Sciences beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Urovant Sciences, Contineum Therapeutics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Urovant Sciencesbase UROV · 🇺🇸 US Percentile in Healthcare Percentile in USA | Regenxbio Inc. RGNX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Indaptus Therapeutics, Inc. INDP · 🇺🇸 US Percentile in Healthcare Percentile in USA | Puma Biotechnology, Inc. PBYI · 🇺🇸 US Percentile in Healthcare Percentile in USA | Phathom Pharmaceuticals, Inc. PHAT · 🇺🇸 US Percentile in Healthcare Percentile in USA | CytomX Therapeutics, Inc. CTMX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Cypherpunk Technologies Inc. CYPH · 🇺🇸 US Percentile in Healthcare Percentile in USA | Contineum Therapeutics, Inc. CTNM · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $512 Mlast known, Jan 1, 2021 · Market dataLast known value: no current one4th of 8 | $513 MOct 6, 2026 · Market data2nd of 8 | $513 MOct 30, 2026 · Market data3rd of 8 | $508 MOct 19, 2026 · Market data5th of 8 | $506 MOct 30, 2026 · Market data6th of 8 | $504 MOct 28, 2026 · Market data7th of 8 | $493 MOct 30, 2026 · Market data8th of 8 | $534 MAug 1, 2026 · Market data1st of 8 | $510 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $170 MFY2025 · SEC3rd of 4 | —— | $228 MFY2025 · SEC1st of 4 | $175 MFY2025 · SEC2nd of 4 | $76 MFY2025 · SEC4th of 4 | —— | —— | $173 M4 ranked |
| Net income (Higher is better) | —— | $-194 MFY2025 · SEC6th of 7 | $-21 MFY2025 · SEC4th of 7 | $31 MFY2025 · SEC1st of 7 | $-221 MFY2025 · SEC7th of 7 | $-17 MFY2025 · SEC3rd of 7 | $5 MFY2025 · SEC2nd of 7 | $-60 MFY2025 · SEC5th of 7 | $-21 M7 ranked |
| Employees (Better neither way: ranked highest first) | —— | 372As on 2021 · Profile1st of 5 | —— | —— | 77As on 2021 · Profile2nd of 5 | 69December 31, 2025 · Profile3rd of 5 | 6December 31, 2025 · Profile5th of 5 | 51December 31, 2025 · Profile4th of 5 | 695 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +104.5%FY2025 · SEC2nd of 492nd96th | ———— | -0.9%FY2025 · SEC3rd of 424th27th | +216.9%FY2025 · SEC1st of 496th98th | -44.8%FY2025 · SEC4th of 45th2nd | ———— | ———— | +51.8%4 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | +14.8%FY2025 · SEC1st of 364th79th | ———— | +0.1%FY2025 · SEC3rd of 327th33rd | ———— | +12.8%FY2025 · SEC2nd of 360th75th | ———— | ———— | +12.8%3 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | -1.6%FY2025 · SEConly one with it34th36th | ———— | ———— | ———— | ———— | -1.6%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | 74.5%FY2025 · SEC2nd of 273rd87th | 87.1%FY2025 · SEC1st of 288th95th | ———— | ———— | ———— | 80.8%2 ranked |
| Operating margin (Higher is better) | ———— | -94.6%FY2025 · SEC4th of 424th11th | ———— | 16.3%FY2025 · SEC1st of 483rd80th | -91.4%FY2025 · SEC3rd of 424th11th | -29.3%FY2025 · SEC2nd of 438th19th | ———— | ———— | -60.4%4 ranked |
| Net margin (Higher is better) | ———— | -113.8%FY2025 · SEC3rd of 421st9th | ———— | 13.6%FY2025 · SEC1st of 484th82nd | -126.3%FY2025 · SEC4th of 420th9th | -22.8%FY2025 · SEC2nd of 441st20th | ———— | ———— | -68.3%4 ranked |
| Free cash flow margin (Higher is better) | ———— | -74.1%FY2025 · SEC2nd of 424th10th | ———— | 18.3%FY2025 · SEC1st of 485th86th | -95.4%FY2025 · SEC3rd of 423rd9th | -99.5%FY2025 · SEC4th of 422nd8th | ———— | ———— | -84.8%4 ranked |
| Return on equity (Higher is better) | ———— | -107.0%FY2025 · SEC5th of 623rd10th | -588.1%FY2025 · SEC6th of 61st1st | 28.0%FY2025 · SEC1st of 694th90th | ———— | -35.3%FY2025 · SEC4th of 651st22nd | 5.1%FY2025 · SEC2nd of 676th51st | -26.1%FY2025 · SEC3rd of 657th25th | -30.7%6 ranked |
| Return on invested capital (Higher is better) | ———— | ———— | ———— | 30.3%FY2025 · SEConly one with it87th88th | ———— | ———— | ———— | ———— | 30.3%— |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | 21.3×price Oct 19, 2026 · Market dataonly one with it34th56th | ———— | ———— | ———— | ———— | 21.3×— |
| Price to sales (Better neither way: ranked highest first) | ———— | 3.3×price Oct 6, 2026 · Market data3rd of 547th65th | ———— | 2.2×price Oct 19, 2026 · Market data4th of 536th51st | 1.8×price Oct 30, 2026 · Market data5th of 531st46th | 6.6×price Oct 28, 2026 · Market data2nd of 564th83rd | 328.9×price Oct 30, 2026 · Market data1st of 598th99th | ———— | 3.3×5 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 5.0×price Oct 6, 2026 · Market data3rd of 566th76th | 162.9×price Oct 30, 2026 · Market data1st of 599th100th | 3.9×price Oct 19, 2026 · Market data4th of 559th70th | ———— | 5.1×price Oct 28, 2026 · Market data2nd of 567th77th | 3.2×price Oct 30, 2026 · Market data5th of 551st64th | 2.0׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 5.0×5 ranked |
| Free cash flow yield (Higher is better) | ———— | -24.6%price Oct 6, 2026 · Market data5th of 629th13th | -2.2%price Oct 30, 2026 · Market data2nd of 661st32nd | 8.2%price Oct 19, 2026 · Market data1st of 693rd81st | -33.0%price Oct 30, 2026 · Market data6th of 625th11th | -15.1%price Oct 28, 2026 · Market data4th of 637th17th | -5.5%price Oct 30, 2026 · Market data3rd of 653rd26th | -10.4%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -10.3%6 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | 0.2×FY2025 · SEConly one with it30th20th | ———— | ———— | ———— | ———— | 0.2×— |
| Net debt to EBITDA (Lower is better) | ———— | ———— | ———— | -0.1×FY2025 · SEConly one with it24th16th | ———— | ———— | ———— | ———— | -0.1×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | 7 of 9FY2025 · SEC1st of 2 | 4 of 9FY2025 · SEC2nd of 2 | —— | —— | —— | 5.5 of 92 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 6 of 19FY2025 · Scorecard2nd of 7 | 1 of 12FY2025 · Scorecard7th of 7 | 12 of 24FY2025 · Scorecard1st of 7 | 3 of 15FY2025 · Scorecard5th of 7 | 6 of 19FY2025 · Scorecard2nd of 7 | 4 of 13FY2025 · Scorecard4th of 7 | 1 of 6FY2025 · Scorecard6th of 7 | 31% passed7 ranked |
| Valuation checks (Higher is better) | —— | 1 of 5FY2025 · Scorecard2nd of 6 | 0 of 4FY2025 · Scorecard5th of 6 | 2 of 6FY2025 · Scorecard1st of 6 | 1 of 5FY2025 · Scorecard2nd of 6 | 1 of 5FY2025 · Scorecard2nd of 6 | 0 of 5FY2025 · Scorecard5th of 6 | —— | 20% passed6 ranked |
| Growth checks (Higher is better) | —— | 3 of 5FY2025 · Scorecard2nd of 7 | 0 of 2FY2025 · Scorecard6th of 7 | 1 of 6FY2025 · Scorecard5th of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 2 of 5FY2025 · Scorecard3rd of 7 | 2 of 2FY2025 · Scorecard1st of 7 | 0 of 1FY2025 · Scorecard6th of 7 | 33% passed7 ranked |
| Profitability checks (Higher is better) | —— | 1 of 5FY2025 · Scorecard4th of 7 | 0 of 3FY2025 · Scorecard5th of 7 | 5 of 6FY2025 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard5th of 7 | 2 of 5FY2025 · Scorecard2nd of 7 | 1 of 3FY2025 · Scorecard3rd of 7 | 0 of 2FY2025 · Scorecard5th of 7 | 20% passed7 ranked |
| Financial health checks (Higher is better) | —— | 1 of 3FY2025 · Scorecard5th of 7 | 1 of 2FY2025 · Scorecard2nd of 7 | 4 of 5FY2025 · Scorecard1st of 7 | 1 of 3FY2025 · Scorecard5th of 7 | 1 of 3FY2025 · Scorecard5th of 7 | 1 of 2FY2025 · Scorecard2nd of 7 | 1 of 2FY2025 · Scorecard2nd of 7 | 50% passed7 ranked |
| Shareholder returns checks (Higher is better) | —— | 0 of 1FY2025 · Scorecard1st of 7 | 0 of 1FY2025 · Scorecard1st of 7 | 0 of 1FY2025 · Scorecard1st of 7 | 0 of 1FY2025 · Scorecard1st of 7 | 0 of 1FY2025 · Scorecard1st of 7 | 0 of 1FY2025 · Scorecard1st of 7 | 0 of 1FY2025 · Scorecard1st of 7 | 0% passed7 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 82.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 0.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 78.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 86.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 99.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 19.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 99.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 82.1%7 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 1742026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 212026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 1572026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 1612026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 1942026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 772026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 1182026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 1577 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | -18.4 pp2026-Q2 against 2026-Q1 · 13F6th of 6 | -2.9 pp2026-Q2 against 2026-Q1 · 13F5th of 6 | +0.5 pp2026-Q2 against 2026-Q1 · 13F4th of 6 | +2.4 pp2026-Q2 against 2026-Q1 · 13F3rd of 6 | +9.2 pp2026-Q2 against 2026-Q1 · 13F1st of 6 | +5.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 6 | —— | +1.5 pp6 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Urovant Sciences: How market caps are worked out; Regenxbio Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Indaptus Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Puma Biotechnology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Phathom Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CytomX Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cypherpunk Technologies Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Contineum Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Urovant Sciences | — | — | — |
| Regenxbio Inc. | -94.6%FY2025 | 24th percentile in Healthcaremedian -7.7%, 674 companies | 11th percentile in USAmedian 3.5%, 2,594 companies |
| Indaptus Therapeutics, Inc. | — | — | — |
| Puma Biotechnology, Inc. | 16.3%FY2025 | 83rd percentile in Healthcaremedian -7.7%, 674 companies | 80th percentile in USAmedian 3.5%, 2,594 companies |
| Phathom Pharmaceuticals, Inc. | -91.4%FY2025 | 24th percentile in Healthcaremedian -7.7%, 674 companies | 11th percentile in USAmedian 3.5%, 2,594 companies |
| CytomX Therapeutics, Inc. | -29.3%FY2025 | 38th percentile in Healthcaremedian -7.7%, 674 companies | 19th percentile in USAmedian 3.5%, 2,594 companies |
| Cypherpunk Technologies Inc. | — | — | — |
| Contineum Therapeutics, Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Urovant Sciences | Regenxbio Inc. | Indaptus Therapeutics, Inc. | Puma Biotechnology, Inc. | Phathom Pharmaceuticals, Inc. | CytomX Therapeutics, Inc. | Cypherpunk Technologies Inc. | Contineum Therapeutics, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $170 MSEC3rd | — | $228 MSEC1st | $175 MSEC2nd | $76 MSEC4th | — | — |
| 2024 | — | $83 MSEC3rd | — | $230 MSEC1st | $55 MSEC4th | $138 MSEC2nd | — | — |
| 2023 | — | $90 MSEC3rd | — | $236 MSEC1st | $1 MSEC5th | $101 MSEC2nd | — | $50 MSEC4th |
| 2022 | — | $113 MSEC2nd | — | $228 MSEC1st | — | $53 MSEC3rd | — | — |
| 2021 | — | — | — | $253 MSEC1st | — | $37 MSEC2nd | $2 MSEC3rd | — |
| 2020 | — | $155 MSEC2nd | — | $225 MSEC1st | — | $68 MSEC3rd | $2 MSEC4th | — |
| 2019 | — | — | — | $272 MSEC1st | — | $27 MSEC2nd | — | — |
| 2018 | — | $219 MSEC2nd | — | $251 MSEC1st | — | $60 MSEC3rd | — | — |
| 2017 | — | $10 MSEC2nd | — | — | — | $72 MSEC1st | — | — |
| 2016 | — | $5 MSEC2nd | — | — | — | $15 MSEC1st | — | — |
| 2015 | — | $8 MSEC2nd | — | — | — | $8 MSEC1st | — | — |
| 2014 | — | $6 MSEC1st | — | — | — | $5 MSEC2nd | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Urovant Sciences#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Regenxbio Inc.RGNX · 🇺🇸 USASame industry: Biotechnology · Similar size: $513 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $513 M (Oct 6, 2026) · revenue $170 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Indaptus Therapeutics, Inc.INDP · 🇺🇸 USASame industry: Biotechnology · Similar size: $513 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $513 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Puma Biotechnology, Inc.PBYI · 🇺🇸 USASame industry: Biotechnology · Similar size: $508 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $508 M (Oct 19, 2026) · revenue $228 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Phathom Pharmaceuticals, Inc.PHAT · 🇺🇸 USASame industry: Biotechnology · Similar size: $506 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $506 M (Oct 30, 2026) · revenue $175 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- CytomX Therapeutics, Inc.CTMX · 🇺🇸 USASame industry: Biotechnology · Similar size: $504 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $504 M (Oct 28, 2026) · revenue $76 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Cypherpunk Technologies Inc.CYPH · 🇺🇸 USASame industry: Biotechnology · Similar size: $493 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $493 M (Oct 30, 2026) · revenue $2 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Contineum Therapeutics, Inc.CTNM · 🇺🇸 USASame industry: Biotechnology · Similar size: $534 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $534 M (Aug 1, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Monopar Therapeutics Inc.MNPR · 🇺🇸 USASame industry: Biotechnology · Similar size: $487 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $487 M (Oct 28, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Arvinas, Inc.ARVN · 🇺🇸 USASame industry: Biotechnology · Similar size: $544 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $544 M (Sep 18, 2026) · revenue $263 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Surrozen, Inc.SRZN · 🇺🇸 USASame industry: Biotechnology · Similar size: $562 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $562 M (Oct 30, 2026) · revenue $3 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- MapLight Therapeutics, Inc.MPLT · 🇺🇸 USASame industry: Biotechnology · Similar size: $558 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $558 M (Sep 15, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- DiaMedica Therapeutics Inc.DMAC · 🇺🇸 USASame industry: Biotechnology · Similar size: $469 M market cap against $512 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $469 M (Oct 28, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.